Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Bibliographic Details
Main Author:	Fei-Yu Diao
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2022-03-01
Series:	Global Medical Genetics
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1736239

Similar Items

Alpelisib as a new treatment option for patients with the PIK3CA mutation. The effectiveness and tolerability of therapy on the example of a clinical case
by: Е. I. Kovalenko, et al.
Published: (2021-06-01)

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
by: D. A. Filonenko, et al.
Published: (2021-12-01)

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
by: Jiah Yeom, et al.
Published: (2023-11-01)

Efficacy of alpelisib with rational use of metformin in HR+/HER2- advanced breast cancer patients with <i>PIK3CA</i> mutations (m): retrospective analysis in routine practice of several Russian centers
by: D. A. Filonenko, et al.
Published: (2025-01-01)

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Antonio Llombart-Cussac, et al.
Published: (2024-05-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
by: Maria Letizia Cataldo, et al.
Published: (2023-07-01)

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer
by: Elizabeth J. Anderson, et al.
Published: (2020-01-01)

Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial
by: Juric, D, et al.
Published: (2018)

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
by: Martin Sterba, et al.
Published: (2023-06-01)

Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer
by: Snježana Ramić, et al.
Published: (2023-01-01)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
by: Ilenia Migliaccio, et al.
Published: (2022-02-01)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
by: Ana Peixoto, et al.
Published: (2023-02-01)

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
by: Anna Passarelli, et al.
Published: (2023-01-01)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
by: Mirko Fillbrunn, et al.
Published: (2022-09-01)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
by: Katherine E. Hutchinson, et al.
Published: (2023-04-01)

PIK3CA mutations in breast cancer with low HER2 / neu expression
by: I. A. Pavlenko, et al.
Published: (2022-12-01)

Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
by: Ana Peixoto, et al.
Published: (2024-04-01)

Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer - ERRATA CORRIGE
by: Snježana Ramić, et al.
Published: (2023-01-01)

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors
by: Ah Reum Lim, et al.
Published: (2024-07-01)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
by: Sara Donzelli, et al.
Published: (2022-07-01)

PIK3CA testing in HR+/HER2− Metastatic Breast Cancer: Real-world data from referral molecular pathology labs
by: K. Venetis, et al.
Published: (2023-11-01)

Predictive and prognostic features of early and locally advanced <i>PIK3CA</i>-mutated luminal HER2-negative breast cancer
by: A. I. Stukan, et al.
Published: (2024-01-01)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
by: Paolo Cossu-Rocca, et al.
Published: (2015-01-01)

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2‐negative metastatic breast cancer
by: Christin Gasch, et al.
Published: (2016-10-01)

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
by: Anja Welt, et al.
Published: (2020-07-01)

P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma
by: Sarah Bouri, et al.
Published: (2020-01-01)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
by: Shohei Shikata, et al.
Published: (2023-11-01)

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia
by: Dora Čerina Pavlinović, et al.
Published: (2024-01-01)

Mutations in <it>PIK3CA </it>are infrequent in neuroblastoma
by: Mazanek Pavel, et al.
Published: (2006-07-01)

Mutations of <it>PIK3CA </it>in gastric adenocarcinoma
by: So Samuel, et al.
Published: (2005-03-01)

An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
by: Aiko Sueta, et al.
Published: (2014-01-01)

HR-positive/HER2-negative breast cancer arising in patients with or without mutation: different biological phenotype and similar prognosis
by: Pu-Chun Li, et al.
Published: (2024-04-01)

PIK3CA mutations in endocrine-resistant breast cancer
by: Caroline Schagerholm, et al.
Published: (2024-05-01)

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
by: Haizhu Chen, et al.
Published: (2023-11-01)

The effects of PIK3CA mutations on cervical cancer
by: Zhang Yuyi
Published: (2024-01-01)

PIK3CA Mutational Analysis of Parathyroid Adenomas
by: Aaliyah Riccardi, et al.
Published: (2020-06-01)

PIK3CA gene mutations in breast carcinoma in Malaysian patients
by: Leong, Vincent Ching Shian, et al.
Published: (2008)

PIK3CA mutations in breast cancer: A Tunisian series.
by: Mariem Ben Rekaya, et al.
Published: (2023-01-01)

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
by: Bardeesy Nabeel, et al.
Published: (2011-02-01)